Source: Neuralstem, Inc.
Posted: December 17, 2007 8:00 am ET
Summary:
Neuralstem, Inc., a biotechnology company in the field of stem cell research developing therapies to treat central nervous system diseases, disorders and injuries. announced that it has entered into a Clinical Trial Research Agreement aimed at treating patients suffering from Ischemic Spastic Paraplegia, a form of spinal cord paralysis, with the Trustees of the University of Pennsylvania through its Department of Anesthesiology and Critical Care.
